Cancer is complex; tumors arise through the accumulation of multiple genetic events. We need medicines that address that complexity. At Tango, we have powerful opportunities to leverage the principles of synthetic lethality and develop new therapies that target mutations current drugs don’t touch. We have an efficient discovery and development process that leverages high-throughput CRISPR screening to identify vulnerabilities in cancer cells. We focus on diseases with high unmet need where patients share a common genetic context. We are committed to developing precise, powerful and safe therapies for the people who need them most.